Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176322 | 0.84 | ENPP2 (0.49) | ENPP2MEN1KMT2ATSHR | |
| SCHEMBL4882490 | 0.84 | TSHR (0.49) | TP53MAPTLMNAMEN1KMT2A | |
| SCHEMBL4940565 | 0.84 | MAPT (0.47) | TP53ENPP2MAPTLMNAMEN1 | |
| SCHEMBL24176343 | 0.83 | ENPP2 (0.46) | TP53ENPP2MAPTLMNAMEN1 | |
| SCHEMBL3145312 | 0.81 | MAPT (0.49) | MAPTLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4878309 | 0.76 | PTGS2 (0.49) | ENPP2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4882030 | 0.76 | PTGS2 (0.46) | ENPP2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4880737 | 0.69 | TP53 (0.41) | TP53ENPP2MAPTLMNAKMT2A | |
| SCHEMBL11739347 | 0.69 | ENPP2 (0.39) | TP53ENPP2MAPTLMNAMEN1 | |
| SCHEMBL11740750 | 0.69 | TP53 (0.40) | TP53ENPP2MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | TP53 2534/4885ENPP2 2226/4885MAPT 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.